A Bioequivalence Study of Levetiracetam Versus Keppra

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00926302
Recruitment Status : Completed
First Posted : June 23, 2009
Last Update Posted : June 23, 2009
Information provided by:
Tri-Service General Hospital

June 18, 2009
June 23, 2009
June 23, 2009
January 2008
February 2009   (Final data collection date for primary outcome measure)
To assess the bioequivalence [ Time Frame: 48 hours ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
A Bioequivalence Study of Levetiracetam Versus Keppra
A Randomized, Single, Two-Way Crossover Pivotal Study to Assess the Bioequivalence Study of Levetiracetam vs. Keppra Administered Under Fasting Conditions to Healthy Adult Subject
The purpose of this study is to assess the bioequivalence of Levetiracetam versus Keppra administered under fasting conditions to healthy adult subjects.
This study is a randomized, single, two-way crossover pivotal study. The pharmacokinetic blood samples and vital signs were obtained before and after administration at scheduled intervals as indicated in the study protocol.
Not Applicable
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
  • Drug: Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)
    Levetiracetam 500mg/tablet Oral once
    Other Names:
    • The test drug Levetiracetam is no brand name.
    • Manufacturer:Lotus Pharmaceutical Co.,Ltd.
  • Drug: Keppra (Levetiracetam - USB SA Pharma Sector)
    Levetiracetam 500mg/tablet oral once
    Other Names:
    • Keppra
    • Manufracturer:USB SA Pharma Sector
  • Experimental: Test drug
    Levetiracetam one period
    Intervention: Drug: Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)
  • Active Comparator: Reference drug
    Keppra one period
    Intervention: Drug: Keppra (Levetiracetam - USB SA Pharma Sector)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
April 2009
February 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Provision of signed written informed consent before enrollment into the study, ability to communicate with the investigators, and to understand and comply with the requirements of the study.
  2. Healthy adult male, aged between 20 and 40 years old.
  3. Body Mass Index between 18.5 and 25 (inclusive).
  4. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, chest x-ray and electrocardiogram.
  5. No significant deviation from normal biochemistry examination.
  6. No significant deviation from normal hematology examination.
  7. No significant deviation from normal urinalysis examination.

Exclusion Criteria:

  1. History of drug or alcohol abuse within the past year.
  2. Medical history of severe drug allergy or sensitivity to analogous drug.
  3. Evidence of acute or chronic disease or having undergone surgery from 4 weeks prior to Period I dosing.
  4. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic, neurological, pulmonary or gastrointestinal pathology.
  5. Ongoing peptic ulcer and constipation.
  6. Planned vaccination during the time course of the study.
  7. Taking any clinical investigation drug from 2 months prior to Period I dosing.
  8. Use of any medication, including herb medicine or vitamins from 4 weeks before the study.
  9. Blood donation of more than 500 mL within the past 3 months.
  10. A positive Hepatitis B surface antigen or positive Hepatitis C antibody result.
  11. A positive test for HIV antibody.
Sexes Eligible for Study: Male
20 Years to 40 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
I-Shin Shiah/The Head of Department of Psychiatry, Tri-Service General Hospital
Tri-Service General Hospital
Not Provided
Principal Investigator: I-Shin Shiah, M.D. Tri-Service General Hospital
Tri-Service General Hospital
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP